May 18 @ 11:30 am – 12:15 pm PDT
Innovation Theater 4
Supported By: Sanofi and Regeneron
Program Description
Explore how type 2 inflammation impacts asthma and COPD, driving exacerbations. Learn about a randomized trial assessing FeNO, lung function, airway volume, and mucus burden in asthma. Discover an option that targets key drivers of inflammation, reduces exacerbations and improve lung function—helping patients breathe better.